Research Keyword: Liposomal amphotericin B

Pulmonary Mucormycosis in Diabetic Patients: A Case Series From a Tertiary Respiratory Center in Sri Lanka

mycolabadmin

This case study describes three patients with diabetes who developed a serious lung infection caused by a rare fungus called mucormycosis. The infection presented with various symptoms like cough, fever, and weight loss, and was diagnosed using lung tissue samples that showed the characteristic fungal structures. Two patients recovered with prolonged antifungal medication treatment, while one patient unfortunately died despite receiving prompt treatment, highlighting how serious this infection can be.

Read More »

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This study reviews how a fungal medication called liposomal amphotericin B is used to prevent serious fungal infections in children with weakened immune systems, particularly those with blood cancers or who have had bone marrow transplants. The researchers found that this medicine prevents infections in about 93% of children, though it does cause side effects like low potassium levels in about 23% of patients. However, the study shows that current use of this medicine is quite varied and more high-quality research is needed to determine the best dosing approach.

Read More »

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a rare but deadly fungal infection that has been increasingly reported in Brazil, especially during the COVID-19 pandemic. This Brazilian medical task force developed practical guidelines for diagnosing and treating this serious infection, which primarily affects people with uncontrolled diabetes or weakened immune systems. The key to survival is early diagnosis combined with aggressive surgery and specific antifungal medications, along with controlling blood sugar and immune system suppression.

Read More »
Scroll to Top